U.S. Markets close in 3 hrs 51 mins

Analysts Expect Incyte to Report Revenue Growth in Third Quarter

Mike Benson
Analysts Expect Incyte to Report Revenue Growth in Third Quarter

As discussed earlier, analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018. The below graph compares the revenues of Incyte since the first quarter of 2017 and estimates for the third quarter of 2018. Incyte’s revenue stream includes product sales, royalty revenues, and other revenues from collaborations. Incyte acquired the commercial rights for Iclusig from Ariad Pharmaceuticals in 2016.